A Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of MYL-1601D with NovoLog® in Type 1 Diabetes Mellitus Patients

Active

Please contact us for more information or to learn if you are eligible to participate.

The aim of this study is to demonstrate the equivalence in the safety and efficacy profile between MYL-1601D and NovoLog® in patients with T1DM.

Principal Investigator	Marcel Twahirwa, MD
Type of Trial	Prospective/Interventional

5323 S. McColl Rd., Edinburg, TX 78539

(956) 362-2390